https://www.selleckchem.com/products/AG-490.html
To estimate the clinical and economic benefits of lenzilumab plus standard of care (SOC) compared with SOC alone in the treatment of hospitalized COVID-19 patients from the National Health Service (NHS) England perspective. A cost calculator was developed to estimate the clinical benefits and costs of adding lenzilumab to SOC in newly hospitalized COVID-19 patients over 28 days. The LIVE-AIR trial results informed the clinical inputs failure to achieve survival without ventilation (SWOV), mortality, time to recovery, intensive care unit
Like
Comment
Share
